Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown significant improvements in patients with advanced non–small cell lung cancer (NSCLC). One of the major issues with ICIs is determining the optimal treatment duration. METHODS: This multicenter, retrospective study analyzed clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hongsik, Kim, Dong‐Wan, Kim, Miso, Lee, Youngjoo, Ahn, Hee Kyung, Cho, Jang Ho, Kim, Il Hwan, Lee, Yun‐Gyoo, Shin, Seong‐Hoon, Park, Song Ee, Jung, Jiyoon, Kang, Eun Joo, Ahn, Myung‐Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297884/
https://www.ncbi.nlm.nih.gov/pubmed/34705268
http://dx.doi.org/10.1002/cncr.33984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297884/
https://www.ncbi.nlm.nih.gov/pubmed/34705268
http://dx.doi.org/10.1002/cncr.33984

Ejemplares similares